FDA Approval - Aducanumab

The news that the FDA in America has approved a new drug for the treatment of Alzheimer’s which targets amyloid sounds of great potential interest to patients with systemic amyloidosis.

Unfortunately this drug, Aducanumab, recognises and targets just misfolded amyloid-β (Aβ), a protein found in the brain which makes Alzheimer’s plaques. This particular protein is not present in systemic amyloidosis, so there is no reason to think that it would be helpful to patients with any of the types of amyloid we see at the NAC.